The Day In Review: Biotech Gives Back Some Gains

August 4, 2005 -- After notching three new all-time highs in a row, biotech put in a down day on Thursday, with the Centient Biotech 200 sinking almost 46 points to close at 3770.35, a 1.2% loss. Corautus passed the second reading of the interim data from its angina drug trial, Amambis said it has a universal flu vaccine almost ready for the clinic, Memory jumped 40% higher, Predix filed for an IPO, Novartis added an indication for Diovan, and Par ended its collaboration with Advancis. More details...